935,186 Shares in Edwards Lifesciences Corporation $EW Acquired by Man Group plc

Key Points

• Man Group plc acquired 935,186 shares of Edwards Lifesciences in the second quarter, valued at approximately $84.6 million and representing 0.16% of the company. Institutional investors collectively own 79.46% of EW.
• Edwards Lifesciences exceeded quarterly expectations, reporting $0.78 in EPS and $1.74 billion in revenue, with revenue rising 13.6% year over year. The company provided full-year 2026 EPS guidance of $2.95–$3.05.
• Analyst sentiment remains favorable, with a consensus “Moderate Buy” rating and an average price target of $100.27; recent targets range from $105 to $110.

Man Group plc bought a new stake in Edwards Lifesciences Corporation (NYSE:EW - Free Report) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 935,186 shares of the medical research company's stock, valued at approximately $84,597,000. Man Group plc owned 0.16% of Edwards Lifesciences as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently bought and sold shares of EW. Hanson & Doremus Investment Management acquired a new stake in shares of Edwards Lifesciences during the 1st quarter worth $25,000. JPL Wealth Management LLC purchased a new stake in Edwards Lifesciences during the third quarter valued at about $25,000. MV Capital Management Inc. acquired a new stake in Edwards Lifesciences during the fourth quarter worth about $26,000. RMG Wealth Management LLC acquired a new stake in Edwards Lifesciences during the first quarter worth about $26,000. Finally, TrinityBridge Ltd purchased a new position in shares of Edwards Lifesciences in the 2nd quarter worth about $27,000. Hedge funds and other institutional investors own 79.46% of the company's stock.

Insider Activity at Edwards Lifesciences

In other news, VP Daniel J. Lippis sold 619 shares of the business's stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $92.03, for a total transaction of $56,966.57. Following the transaction, the vice president directly owned 40,034 shares of the company's stock, valued at approximately $3,684,329.02. The trade was a 1.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Andrew M. Dahl sold 568 shares of the company's stock in a transaction on Friday, May 29th. The shares were sold at an average price of $86.08, for a total transaction of $48,893.44. Following the completion of the transaction, the senior vice president owned 15,334 shares of the company's stock, valued at $1,319,950.72. This trade represents a 3.57% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 2,425 shares of company stock valued at $219,199 in the last ninety days. 0.31% of the stock is owned by corporate insiders.

Edwards Lifesciences Trading Up 0.5%

NYSE:EW opened at $90.92 on Wednesday. The business's 50-day moving average is $89.35 and its two-hundred day moving average is $84.82. The firm has a market capitalization of $52.35 billion, a PE ratio of 52.25, a price-to-earnings-growth ratio of 2.37 and a beta of 0.85. Edwards Lifesciences Corporation has a 12 month low of $72.30 and a 12 month high of $96.29. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.52 and a quick ratio of 3.77.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.74 by $0.04. The company had revenue of $1.74 billion during the quarter, compared to the consensus estimate of $1.70 billion. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The company's revenue was up 13.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.67 earnings per share. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Research analysts predict that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on EW shares. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Edwards Lifesciences in a research note on Friday, July 17th. TD Cowen reissued a "buy" rating on shares of Edwards Lifesciences in a research report on Tuesday, July 21st. JPMorgan Chase & Co. raised their price target on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the company an "overweight" rating in a report on Friday, July 24th. BTIG Research lifted their price target on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the company a "buy" rating in a research report on Tuesday, June 30th. Finally, Mizuho boosted their price objective on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the stock an "outperform" rating in a research note on Wednesday, July 15th. Seventeen equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $100.27.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source